Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.
Copyright 2026 NPR
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.
